Part Two: Peter Attia and the Cult of Longevity
Summary
This episode of Behind the Bastards features guest Dr. Kaveh Hoda discussing the controversial practices of longevity physician Peter Attia. The hosts critique Attia’s "Medicine 3.0" framework, arguing that his aggressive testing and off-label drug prescriptions for wealthy clients lack sufficient evidence and create a two-tiered healthcare system. They also examine Attia’s past work at McKinsey & Company, highlighting the firm’s role in the opioid crisis, and debate the medical validity of his recommendations for metabolic syndrome and cancer prevention.
Topics discussed
Intro, sponsor reads, and recap of Peter Attia's background
Attia's time at McKinsey and the opioid crisis
McKinsey's role in Purdue Pharma's OxyContin marketing
Transition to medicine and the rise of 'Medicine 3.0'
Critique of science-washing and concierge medicine models
The longevity industry and two-tiered healthcare systems
Attia's podcast, book 'Outlive', and celebrity clientele
Defining metabolic syndrome and the 'one marker' controversy
Over-testing, expensive diagnostics, and screening guidelines
Patient dissatisfaction with gatekeeping and preventive care
Sponsor breaks and podcast promotions
UC Davis study: patient satisfaction vs. health outcomes
Risks of continuous glucose monitoring and unnecessary intervention
Healthcare spending, end-of-life care, and death panels
Cherry-picking longevity data and dietary restrictions
Rapamycin, ivermectin, and the risks of experimental drugs
Attia's association with RFK Jr. and anti-vaccine narratives
Assessing Attia's 'bastard' status and Medicine 2.0 vs 3.0
Sponsor breaks and podcast promotions
Attia's connection to Jeffrey Epstein and the DOJ files
Analysis of emails: Attia, Epstein, and victim recruitment
Attia's behavior during a patient's ICU stay and ethical failures
Conclusion: Attia as a consequential medical influencer
Outro and final sponsor reads
Listen ad-free on Castria